Connect with us

News

Jeremy Hunt hinted at the end of pay restraint for NHS Staff

Published

on

Jeremy Hunt has hinted at the end of pay restraint during a conference for NHS leaders in Liverpool today.

Following his reappointment, Jeremy Hunt, has hinted at the end of pay restraint for healthcare staff. During a conference with NHS Leaders in Liverpool today he has promised to discuss the issue further with the chancellor.

He is due to meet with RCN chief executive and General Secretary Janet Davies in the coming weeks to discuss the issue further.

NHS Staff have been subjected to an on-going 1% pay cap following recommendations from the NHS Pay Review Body.

During the this speech he said; “I’ve said many times, I have a great deal of sympathy for the case that nurses amongst others have made on the issue of pay”.

“I think they do an absolutely brilliant job, they work very hard and need to factor in that there is an enormous amount of good will and time given free of charge because people care about their jobs – and see it not as a job but as a vocation”.

“We have our budget that we have to live within, but public sector pay is a matter for the chancellor, because it is policy that is set across the whole of government”.

“But I have had a very constructive letter from Janet Davies, head of the RCN, since I came back into office and will be meeting with her. And I will make sure our conversation is reflected back to the chancellor before he makes that decision”.

Finally, he added that he had noted an “enormous amount of goodwill” among staff who worked extra hours for no extra money.

Continue Reading
Advertisement
1 Comment

1 Comment

  1. Ella murphy

    15th June 2017 at 8:35 pm

    Goodwill has nothing to do with it,we as nurses have to complete paperwork during our shift,due to understaffing,high demands,I’ll people etc, we cannot fulfill this during normal shift hours and HAVE to stay behind to update paperwork..it’s very patronising from mr hunt and co to make comments like this!

Leave a Reply

Your email address will not be published. Required fields are marked *

Midwifery

Royal College of Midwives to end campaign to promote ‘normal births’

Published

on

By

The Royal College of Midwives ends their campaign for “normal births” to avoid making mothers who opt for medical interventions feel like failures.

The Royal College of Midwives (RCM) has been running a continuous campaign since 2005 to encourage expectant mothers to give birth without medical interventions such as; epidurals, inductions and caesareans.

Currently, around 40% of mothers give birth without medical interventions. 20% less than 30 years ago. But experts say a significant number of these are due to the increase in more risky pregnancies.

Prof Cathy Warwick, the Chief Executive of the RCM, said;

“There was a danger that if you just talk about normal births – and particularly if you call it a campaign – it kind of sounds as if you’re only interested in women who have a vaginal birth without intervention”.

“What we don’t want to do is in any way contribute to any sense that a woman has failed because she hasn’t had a normal birth. Unfortunately, that seems to be how some women feel.”

“What we don’t want to do is in any way contribute to any sense that a woman has failed because she hasn’t had a normal birth. Unfortunately that seems to be how some women feel.”

Midwives, will instead, start to use the term “physiological births” to describe those without interventions.

Continue Reading

News

Pancreatic cancer patients to have routine access to life extending drug after new deal

Published

on

NICE has recommended nab-paclitaxel for routine NHS use after the company agreed a confidential price discount and provided more evidence on its effectiveness.

Nab-paclitaxel, also known as Abraxane, made by Celgene will be routinely available as an option for patients with pancreatic cancer that has progressed.

When Abraxane is added to a standard chemotherapy, called gemcibatine the evidence has found it extends life by an average of 2.4 months.

If other combination chemotherapy treatments are unsuitable for a patient, NICE recommends offering Abraxane instead of this standard chemotherapy on its own.

It works by blocking the action of the proteins within cancer cells that cause them to grow and divide.

NICE has reviewed its guidance from 2015 which did not recommend Abraxane for routine NHS use for not being cost-effective.

Professor Carole Longson, director of the centre for health technology evaluation at NICE, said: The life expectancy of pancreatic cancer is poor, with patients usually living for only up to 6 months. It’s incredibly important that patients and families affected by this disease are able to have routine access to this life extending treatment.”

There are almost 10,000 new cases of pancreatic cancer each year in the UK, and less than 1% survive for 10 or more years.

This is a final appraisal determination for Abraxane. The company, healthcare professionals and patient/carer organisations now have until Friday 1 September to appeal the decision.

Continue Reading

Trending